On June 26, 2025, an advisory panel of the U.S. Centers for Disease Control and Prevention (CDC) recommended the use of Merck's respiratory syncytial virus (RSV) therapy, Enflonsia (clesrovimab), for infants 8 months or younger.
The recommendation specifically targets infants whose mothers did not receive a preventive shot during pregnancy. This endorsement from a key public health body is crucial for the widespread adoption and commercial success of the newly approved therapy.
This positive recommendation reinforces the clinical value of clesrovimab in protecting vulnerable infants from RSV. It is expected to facilitate market access and integration into pediatric immunization guidelines, contributing to Merck's infectious disease revenue.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.